This continuing education program will highlight recent advances in the treatment and management of breast cancer, with a focus on HER2-targeted therapy. The expert faculty will review the current treatment landscape for both early stage and metastatic breast cancer. Recent clinical trial data of emerged and emerging agents, particularly best practices for optimizing HER2-targeted therapy continuing into the adjuvant setting, will be reviewed and clinical relevance debated. At the conclusion of this CME program, learners will better understand the clinical implications of recent clinical trial data, to improve outcomes and quality of life in patients with breast cancer.
Oncologists, primary care physicians, internists, nurse practitioners, nurses, and other healthcare providers involved in the management of patients with breast cancer
- Discuss the biologic and molecular pathogenesis of breast cancer to understand how to develop strategies for early intervention and effective diagnosis of patients
- Assess clinical trial data of novel pharmaceuticals for the treatment of patients with breast cancer
- Work with the interprofessional team to develop individualized treatment strategies to achieve optimal outcomes in patients with breast cancer
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Erika P. Hamilton, MD
|Consultant/Advisor: AstraZenecea; Black Diamond Therapeutics, Inc.; Boehringer Ingelheim; Daiichi Sankyo; Eli Lilly and Company; Genentech Inc.; NanoString Technologies; Novartis Pharmaceuticals Corporation; Mersana Therapeutics; Pfizer Inc.; Puma Biotechnology; Roche; Silverback Therapeutics
Grant/Research Support: AbbVie, Inc.; Acerta Pharma; ArQule, Inc.; AstraZenecea; BerGenBio; Boehringer Ingelheim; Curis, Inc.; Daiichi Sankyo; Eisai Co., Ltd.; eFFECTOR Therapeutics; Eli Lilly and Company; EMD Serono; FUJIFILM Pharmaceuticals U.S.A., Inc.; Genentech, Inc.; H3 Biomedicine; Immunomedics; Lycera Corporation; Hutchison MacroGenics; Leap Therapeutics; MediPharma; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Medivation; MedImmune; Novartis Pharmaceuticals Corporation; NuCana plc; OncoMed Pharmaceuticals, Inc.; Pfizer Inc.; Puma Biotechnology; Radius Health; Regeneron Pharmaceuticals; Seattle Genetics Inc.; Taiho Pharmaceuticals; Takeda Pharmaceutical Company; TapImmune; Tesaro; Rgenix; Roche; Stemcentrx; Syndax Pharmaceuticals Inc.; Verastem Oncology; Zymeworks
|Denise Yardley, MD
|Consultant/Advisor: Biotheranostics; Bristol-Myers Squibb Company; Celgene Corporation; Daiichi Sankyo; Eisai Co., Ltd.; Eli Lilly and Company; Genentech, Inc.; Immunomedics; NanoString Technologies; Novartis Pharmaceuticals Corporation; Roche
Grant/Research Support: AbbVie, Inc.; AstraZenecea; Clovis Oncology; Daiichi Sankyo; Eli Lilly and Company; Eisai Co., Ltd.; Genentech Inc.; InventisBio Co. Ltd.; MacroGenics, Inc.; MedImmune; Medivation; Merck & Co.; Novartis Pharmaceuticals Corporation; Oncothyreon, Inc.; Pfizer Inc.; Roche; Syndax Pharmaceuticals Inc.; Tesaro Inc.
Speaker’s Bureau: Genentech, Inc.; Novartis Pharmaceuticals Corporation; Roche
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this live material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
This activity has been supported by an independent educational grant from Daiichi Sankyo.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Daiichi Sankyo do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
1.Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions andcomplete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
6. Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].